Cepharanthine sensitizes gastric cancer cells to chemotherapy by targeting TRIB3-FOXO3-FOXM1 axis to inhibit autophagy
This study links the TRIB3-FOXO3-FOXM1 axis with chemotherapy efficacy. Our findings demonstrated that CEP inhibits autophagy by modulating the FOXO3-FOXM1 axis. When combined with chemotherapy drugs (DOX and CIS), CEP, as an autophagy inhibitor, can limit TRIB3 protein expression, thereby regulating the FOXO3-FOXM1 axis and enhancing its ability to prevent gastric cancer growth. These findings may contribute to improving the prognosis of patients with gastric cancer. Furthermore, these results enrich the fundamental understanding of how autophagy inhibition can enhance clinical cancer treatment efficacy and provide insights into the potential mechanisms by which CEP functions as an anti-tumor drug, thereby exploring its value for clinical application.
Authors
- Yuanyuan Fang (ORCID: https://orcid.org/0000-0001-6133-9583)
- Wensheng Qiu (ORCID: https://orcid.org/0000-0002-9817-1857)
- Liang Zhu (ORCID: https://orcid.org/0000-0002-1561-553X)
- Wei-wei Qi (ORCID: https://orcid.org/0000-0001-6608-2799)
- Zhong-Kun Lin
- Shasha Wang (ORCID: https://orcid.org/0000-0002-3172-3899)
- Jialin Song (ORCID: https://orcid.org/0000-0001-5633-9909)
- Yangyang Lu (ORCID: https://orcid.org/0000-0002-2933-3461)
- Siyi Zhang (ORCID: https://orcid.org/0000-0002-7730-9546)
- Rui Wang (ORCID: https://orcid.org/0009-0008-1807-9585)
- Jing Guo (ORCID: https://orcid.org/0009-0005-8497-9758)
Institutions
- Qingdao University (CN)
- Affiliated Hospital of Qingdao University (CN)
- Qingdao Municipal Hospital (CN)
Publication Details
- Journal
- Phytomedicine
- Published
- 2024-10-16
- DOI
- https://doi.org/10.1016/j.phymed.2024.156161
- Citations
- 16
- Primary Topic
- FOXO transcription factor regulation
- Type
- article
- Field-Weighted Citation Impact
- 3.74
Funders
- Beijing Xisike Clinical Oncology Research Foundation